{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T12:05:30Z","timestamp":1789646730545,"version":"4.0.0"},"reference-count":166,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibodies"],"abstract":"<jats:p>Cancer progression and therapeutic resistance are shaped by reciprocal dynamic interactions between malignant cells and the metabolically altered tumor microenvironment (TME). Tumor-associated hypoxia, glucose and amino acid competition, extracellular acidity, lactate accumulation, adenosine, prostaglandin E2 (PGE2) and other metabolic signals can remodel immune cell function and determine whether inflammation is tumoricidal or tumor-supportive. Although B lymphocytes have traditionally been viewed as antibody-producing cells, tumor-infiltrating B (TIL-B) cells comprise functionally heterogeneous populations that can act as antigen-presenting cells, cytokine and chemokine producers, antibody-secreting cells, cytotoxic effectors, regulatory B cells (Bregs) and organizers of tertiary lymphoid structures (TLSs). Their functional state is strongly influenced by the metabolic and spatial context in which they reside. This review focuses on the intersection of B cell biology and tumor immunometabolism, emphasizing how hypoxia, lactate, nutrient limitation, adenosine, PGE2, kynurenine and B cell-derived \u03b3-aminobutyric acid (GABA) may shape B cell states and their interactions with myeloid and lymphoid cells. We discuss how metabolically conditioned Bregs and immunoglobulin (Ig)A-skewed humoral responses can contribute to immune suppression, whereas metabolically competent antigen-presenting, IgG-biased and TLS-associated B cell responses may support effective anti-tumor immunity. Importantly, the effects are tumor type- and context-dependent: B cell\/TLS signatures are associated with favorable outcomes in several breast, lung and other solid tumors, whereas B cell-centered immune landscapes can be suppressed or neutral in pancreatic cancer and IgA-dominated responses may be unfavorable in selected malignancies. We further examine how these states may influence sensitivity or resistance to immune checkpoint blockade, chemotherapy, radiotherapy and cellular therapies. Finally, we highlight B cell metabolic pathways as potential therapeutic entry points and identify priorities for spatial metabolomics and prospective interventional studies.<\/jats:p>","DOI":"10.3390\/antib15050087","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T11:41:35Z","timestamp":1789645295000},"page":"87","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["B Cells and Tumor Immunometabolism: Emerging Insights into Immune Regulation and Therapeutic Resistance"],"prefix":"10.3390","volume":"15","author":[{"given":"Swati","family":"Gupta","sequence":"first","affiliation":[{"name":"Centre for Interdisciplinary Sciences, JIS Institute of Advanced Studies and Research, JIS School of Medical Science & Research Campus, JIS University, Santragachi, Howrah 711112, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandip","family":"Rath","sequence":"additional","affiliation":[{"name":"Centre for Interdisciplinary Sciences, JIS Institute of Advanced Studies and Research, JIS School of Medical Science & Research Campus, JIS University, Santragachi, Howrah 711112, West Bengal, India"},{"name":"Biochemistry Department, Tata Medical Centre, 14 Major Arterial Road, Rajarhat, Newtown, Kolkata 700156, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surathi","family":"Maiti","sequence":"additional","affiliation":[{"name":"Centre for Interdisciplinary Sciences, JIS Institute of Advanced Studies and Research, JIS School of Medical Science & Research Campus, JIS University, Santragachi, Howrah 711112, West Bengal, India"},{"name":"Department of Microbiology, College of Medicine and Jawaharlal Nehru Memorial Hospital, The West Bengal University of Health Sciences, Kalyani 741235, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tapas","family":"Das","sequence":"additional","affiliation":[{"name":"Centre for Interdisciplinary Sciences, JIS Institute of Advanced Studies and Research, JIS School of Medical Science & Research Campus, JIS University, Santragachi, Howrah 711112, West Bengal, India"},{"name":"Department of Health & Family Welfare, Revised National Tuberculosis Control Programme (RNTCP), Government of West Bengal, Barasat 700124, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4443-4284","authenticated-orcid":false,"given":"Farhat","family":"Afrin","sequence":"additional","affiliation":[{"name":"Centre for Interdisciplinary Sciences, JIS Institute of Advanced Studies and Research, JIS School of Medical Science & Research Campus, JIS University, Santragachi, Howrah 711112, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1002\/ijc.35278","article-title":"The GLOBOCAN 2022 cancer estimates: Data sources, methods, and a snapshot of the cancer burden worldwide","volume":"156","author":"Filho","year":"2025","journal-title":"Int. J. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"89","DOI":"10.14715\/cmb\/2024.70.5.13","article-title":"Recent advances in immunotherapy in cancer treatment","volume":"70","author":"Patel","year":"2024","journal-title":"Cell. Mol. Biol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.trecan.2025.04.004","article-title":"Tissue mechanics in tumor heterogeneity and aggression","volume":"11","author":"Finger","year":"2025","journal-title":"Trends Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/s12276-023-01020-1","article-title":"Metabolic reprogramming and epigenetic modifications in cancer: From the impacts and mechanisms to the treatment potential","volume":"55","author":"Xu","year":"2023","journal-title":"Exp. Mol. Med."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Katopodi, T., Petanidis, S., Anestakis, D., Charalampidis, C., Chatziprodromidou, I., Floros, G., Eskitzis, P., Zarogoulidis, P., Koulouris, C., and Sevva, C. (2024). Tumor cell metabolic reprogramming and hypoxic immunosuppression: Driving carcinogenesis to metastatic colonization. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1325360"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/eji.200535744","article-title":"Toll-like receptor stimulation as a third signal required for activation of human naive B cells","volume":"36","author":"Ruprecht","year":"2006","journal-title":"Eur. J. Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"4977","DOI":"10.4049\/jimmunol.1001323","article-title":"CD20+ B cells: The other tumor-infiltrating lymphocytes","volume":"185","author":"Nelson","year":"2010","journal-title":"J. Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"5597","DOI":"10.1158\/0008-5472.CAN-16-0431","article-title":"The emerging role of B cells in tumor immunity","volume":"76","author":"Tsou","year":"2016","journal-title":"Cancer Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.ccell.2023.02.017","article-title":"B cells in the tumor microenvironment: Multi-faceted organizers, regulators, and effectors of anti-tumor immunity","volume":"41","author":"Laumont","year":"2023","journal-title":"Cancer Cell"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Yang, H., Zhang, Z., Li, J., Wang, K., Zhu, W., and Zeng, Y. (2024). The dual role of B cells in the tumor microenvironment: Implications for cancer immunology and therapy. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms252111825"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.trecan.2024.07.009","article-title":"CD4+ T cells in antitumor immunity","volume":"10","author":"Montauti","year":"2024","journal-title":"Trends Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1186\/s12967-025-06291-y","article-title":"New insights on anti-tumor immunity of CD8+ T cells: Cancer stem cells, tumor immune microenvironment and immunotherapy","volume":"23","author":"Lin","year":"2025","journal-title":"J. Transl. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1372995","DOI":"10.3389\/fsysb.2024.1372995","article-title":"Crosstalking with dendritic cells: A path to engineer advanced T Cell immunotherapy","volume":"4","author":"Schafer","year":"2024","journal-title":"Front Syst. Biol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/s41416-021-01674-6","article-title":"B cell-related gene signature and cancer immunotherapy response","volume":"126","author":"Lundberg","year":"2022","journal-title":"Br. J. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/s41586-021-04082-1","article-title":"B cell-derived GABA elicits IL-10+ macrophages to limit anti-tumour immunity","volume":"599","author":"Zhang","year":"2021","journal-title":"Nature"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41392-024-01765-9","article-title":"Harnessing innate immune pathways for therapeutic advancement in cancer","volume":"9","author":"Hu","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1146\/annurev-pathmechdis-032221-115501","article-title":"Innate Immunity and Cancer Pathophysiology","volume":"17","author":"Maiorino","year":"2022","journal-title":"Annu. Rev. Pathol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41568-019-0235-4","article-title":"CD8+ T cell states in human cancer: Insights from single-cell analysis","volume":"20","author":"Thommen","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Hsieh, C.H., Chuang, P.C., and Liu, Y.W. (2025). Beyond adaptive immunity: Trained innate immune responses as a novel frontier in hepatocellular carcinoma therapy. Cancers, 17.","DOI":"10.3390\/cancers17071250"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41392-023-01480-x","article-title":"Epigenetic regulation in the tumor microenvironment: Molecular mechanisms and therapeutic targets","volume":"8","author":"Yang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_21","first-page":"1","article-title":"Immunity, hypoxia, and metabolism\u2013the M\u00e9nage \u00e0 Trois of cancer: Implications for immunotherapy","volume":"100","author":"Audige","year":"2020","journal-title":"Physiol. Rev."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41392-025-02335-3","article-title":"Microbiota in cancer: Current understandings and future perspectives","volume":"11","author":"Yao","year":"2026","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Lu, C., Liu, Y., Ali, N.M., Zhang, B., and Cui, X. (2023). The role of innate immune cells in the tumor microenvironment and research progress in anti-tumor therapy. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1039260"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Lasorsa, F., Rutigliano, M., Milella, M., Ferro, M., Pandolfo, S.D., Crocetto, F., Tataru, O.S., Autorino, R., Battaglia, M., and Ditonno, P. (2023). Cellular and molecular players in the tumor microenvironment of renal cell carcinoma. J. Clin. Med., 12.","DOI":"10.3390\/jcm12123888"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Czajka-Francuz, P., Prendes, M.J., Mankan, A., Quintana, A., Pabla, S., Ramkissoon, S., Jensen, T.J., Peiro, S., Severson, E.A., and Achyut, B.R. (2023). Mechanisms of immune modulation in the tumor microenvironment and implications for targeted therapy. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1200646"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/s12276-023-01028-7","article-title":"Immune regulation through tryptophan metabolism","volume":"55","author":"Seo","year":"2023","journal-title":"Exp. Mol. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e014745","DOI":"10.1136\/jitc-2025-014745","article-title":"Spatial and phenotypic plasticity of B cells in remodeling the tumor microenvironment","volume":"14","author":"Gao","year":"2026","journal-title":"J. Immunother. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/j.ccell.2024.09.010","article-title":"The hallmarks of cancer immune evasion","volume":"42","author":"Galassi","year":"2024","journal-title":"Cancer Cell"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"5999","DOI":"10.1073\/pnas.1602069113","article-title":"NLRC5\/MHC class I transactivator is a target for immune evasion in cancer","volume":"113","author":"Yoshihama","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s11033-025-11367-5","article-title":"Gatekeepers of immunity: Mechanisms and regulation of immune checkpoints and their role in immune-privileged sites","volume":"53","author":"Abadi","year":"2026","journal-title":"Mol. Biol. Rep."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12943-024-02208-3","article-title":"Myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment and their targeting in cancer therapy","volume":"24","author":"He","year":"2025","journal-title":"Mol. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Pawar, J.S., Salam, M.A., Dipto, M.S., Al-Amin, M.Y., Salam, M.T., Sengupta, S., Kumari, S., Gujjari, L., and Yadagiri, G. (2025). Cancer-Associated fibroblasts: Immunosuppressive crosstalk with tumor-infiltrating immune cells and implications for therapeutic resistance. Cancers, 17.","DOI":"10.3390\/cancers17152484"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41392-026-02705-5","article-title":"Pancreatic ductal adenocarcinoma: Integrating molecular insights for targeted interventions","volume":"11","author":"Nagaraju","year":"2026","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.cpt.2022.12.002","article-title":"Role of T cells in cancer immunotherapy: Opportunities and challenges","volume":"1","author":"Ahmed","year":"2023","journal-title":"Cancer Pathog. Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1007\/s00262-019-02374-0","article-title":"CD4+ T cells indirectly kill tumor cells via induction of cytotoxic macrophages in mouse models","volume":"68","author":"Bogen","year":"2019","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/jhbp.12148","article-title":"Carbon-ion irradiation together with autophagy inhibition and immune checkpoint inhibitors protect against pancreatic cancer development in mouse model","volume":"32","author":"Sudo","year":"2025","journal-title":"J. Hepato-Biliary-Pancreat. Sci."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"13906","DOI":"10.1021\/acsnano.4c17491","article-title":"Zinc ion-coordinated sericin calcium phosphate nanovaccines induce hyperactive dendritic cells and synergistic activation of T cells for cancer immunotherapy","volume":"19","author":"Huang","year":"2025","journal-title":"ACS Nano"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1186\/s12967-024-05134-6","article-title":"CD8+ T cell-based cancer immunotherapy","volume":"22","author":"Chen","year":"2024","journal-title":"J. Transl. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1186\/s12935-024-03525-9","article-title":"Th17 cell function in cancers: Immunosuppressive agents or anti-tumor allies?","volume":"24","author":"Anvar","year":"2024","journal-title":"Cancer Cell Int."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.it.2024.02.005","article-title":"Regulation and impact of tumor-specific CD4+ T cells in cancer and immunotherapy","volume":"45","author":"Guo","year":"2024","journal-title":"Trends Immunol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1002\/mc.23730","article-title":"Deciphering CD4+ T cell-mediated responses against cancer","volume":"63","author":"Kirkpatrick","year":"2024","journal-title":"Mol. Carcinog."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s12967-025-06167-1","article-title":"Role of CD4+ T cells in cancer immunity: A single-cell sequencing exploration of tumor microenvironment","volume":"23","author":"An","year":"2025","journal-title":"J. Transl. Med."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Li, X., and Song, S. (2025). Dissecting the role of T cell exhaustion in cancer progression: A multifaceted approach. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1646292"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Lv, Z., Yang, R., Zhang, K., Wang, R., Shi, X., Wu, J., Liu, L., and Jiao, J. (2025). The dual immunomodulatory role of B cells in tumorigenesis: Mechanisms, microenvironment crosstalk, and therapeutic implications. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1649812"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s12935-025-03668-3","article-title":"Tumor-infiltrating B cells in non-small cell lung cancer: Current insights and future directions","volume":"25","author":"Jiang","year":"2025","journal-title":"Cancer Cell Int."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1016\/j.celrep.2019.10.018","article-title":"Aryl hydrocarbon receptor contributes to the transcriptional program of IL-10-producing regulatory B cells","volume":"29","author":"Piper","year":"2019","journal-title":"Cell Rep."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/cmi.2017.35","article-title":"B cell regulation in cancer and anti-tumor immunity","volume":"14","author":"Sarvaria","year":"2017","journal-title":"Cell. Mol. Immunol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/leu.2015.174","article-title":"The BAFF receptor TACI controls IL-10 production by regulatory B cells and CLL B cells","volume":"30","author":"Vincent","year":"2016","journal-title":"Leukemia"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s00262-024-03936-7","article-title":"Dynamic roles of tumor-infiltrating B lymphocytes in cancer immunotherapy","volume":"74","author":"Song","year":"2025","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s40425-016-0145-x","article-title":"B cell regulation of the anti-tumor response and role in carcinogenesis","volume":"4","author":"Schwartz","year":"2016","journal-title":"J. Immunother. Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/j.jid.2019.02.016","article-title":"Regulatory B1a cells suppress melanoma tumor immunity via IL-10 production and inhibiting T helper type 1 cytokine production in tumor-infiltrating CD8+ T cells","volume":"139","author":"Kobayashi","year":"2019","journal-title":"J. Investig. Dermatol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/imr.12859","article-title":"The role of B cell antigen presentation in the initiation of CD4+ T cell response","volume":"296","author":"Hua","year":"2020","journal-title":"Immunol. Rev."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"77","DOI":"10.4049\/jimmunol.2001173","article-title":"CD40L-stimulated B lymphocytes are polarized toward APC functions after exposure to IL-4 and IL-21","volume":"207","author":"Gagnon","year":"2021","journal-title":"J. Immunol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"155169","DOI":"10.1016\/j.prp.2024.155169","article-title":"Participation of B cell in immunotherapy of cancer","volume":"255","author":"Chandnani","year":"2024","journal-title":"Pathol. Res. Pract."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.coi.2021.06.003","article-title":"New insights into B cells as antigen presenting cells","volume":"70","author":"Ghosh","year":"2021","journal-title":"Curr. Opin. Immunol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"102300","DOI":"10.1016\/j.gde.2024.102300","article-title":"Transcription factor\u2013mediated reprogramming to antigen-presenting cells","volume":"90","author":"Ascic","year":"2025","journal-title":"Curr. Opin. Genet. Dev."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/nri3857","article-title":"Antibody-independent functions of B cells: A focus on cytokines","volume":"15","author":"Shen","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"23674","DOI":"10.1073\/pnas.2010981117","article-title":"Circulation of gut-preactivated na\u00efve CD8+ T cells enhances antitumor immunity in B cell-defective mice","volume":"117","author":"Akrami","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/s41568-024-00728-0","article-title":"Tertiary lymphoid structures in anticancer immunity","volume":"24","author":"Teillaud","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Tan, R., Nie, M., and Long, W. (2022). The role of B cells in cancer development. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.958756"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Milardi, G., and Lleo, A. (2023). Tumor-infiltrating B lymphocytes: Promising immunotherapeutic targets for primary liver cancer treatment. Cancers, 15.","DOI":"10.3390\/cancers15072182"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41568-024-00761-z","article-title":"Convergent inducers and effectors of T cell paralysis in the tumour microenvironment","volume":"25","author":"Hanahan","year":"2025","journal-title":"Nat. Rev. Cancer"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Kdimati, S., Mullins, C.S., and Linnebacher, M. (2021). Cancer-cell-derived IgG and its potential role in tumor development. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222111597"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Willsmore, Z.N., Harris, R.J., Crescioli, S., Hussein, K., Kakkassery, H., Thapa, D., Cheung, A., Chauhan, J., Bax, H.J., and Chenoweth, A. (2021). B cells in patients with melanoma: Implications for treatment with checkpoint inhibitor antibodies. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.622442"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/s41586-020-03144-0","article-title":"IgA transcytosis and antigen recognition govern ovarian cancer immunity","volume":"591","author":"Biswas","year":"2021","journal-title":"Nature"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1038\/s41467-024-47425-y","article-title":"Molecular patterns of resistance to immune checkpoint blockade in melanoma","volume":"15","author":"Lauss","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1158\/0008-5472.CAN-21-2376","article-title":"IgA-dominated humoral immune responses govern patients\u2019 outcome in endometrial cancer","volume":"82","author":"Mandal","year":"2022","journal-title":"Cancer Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e1294296","DOI":"10.1080\/2162402X.2017.1294296","article-title":"B cells and the humoral response in melanoma: The overlooked players of the tumor microenvironment","volume":"6","author":"Chiaruttini","year":"2017","journal-title":"Oncoimmunology"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1038\/s41418-023-01229-7","article-title":"Characterizing the regulatory Fas (CD95) epitope critical for agonist antibody targeting and CAR-T bystander function in ovarian cancer","volume":"30","author":"Mondal","year":"2023","journal-title":"Cell Death Differ."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1158\/2159-8290.CD-20-0756","article-title":"A critical role for Fas-mediated off-target tumor killing in T-cell immunotherapy","volume":"11","author":"Upadhyay","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1016\/j.chembiol.2022.08.006","article-title":"In vivo bioluminescence imaging of granzyme B activity in tumor response to cancer immunotherapy","volume":"29","author":"Chen","year":"2022","journal-title":"Cell Chem. Biol."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Valan\u010di\u016bt\u0117, A., Mathieson, L., O\u2019Connor, R.A., Scott, J.I., Vendrell, M., Dorward, D.A., Akram, A.R., and Dhaliwal, K. (2022). Phototherapeutic induction of immunogenic cell death and CD8+ T cell-granzyme B mediated cytolysis in human lung cancer cells and organoids. Cancers, 14.","DOI":"10.3390\/cancers14174119"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41586-021-03239-2","article-title":"Affinity-coupled CCL22 promotes positive selection in germinal centres","volume":"592","author":"Liu","year":"2021","journal-title":"Nature"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"110078","DOI":"10.1016\/j.intimp.2023.110078","article-title":"CCL17 acts as an antitumor chemokine in micromilieu-driven immune skewing","volume":"118","author":"Li","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"268","DOI":"10.4049\/jimmunol.2300718","article-title":"CCL22 Induces the Polarization of Immature Dendritic Cells into Tolerogenic Dendritic Cells in Radiation-Induced Lung Injury through the CCR4\u2013Dectin2\u2013PLC-\u03b32\u2013NFATC2\u2013Nr4a2\u2013PD-L1 Signaling Pathway","volume":"213","author":"Liu","year":"2024","journal-title":"J. Immunol."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Jorapur, A., Marshall, L.A., Jacobson, S., Xu, M., Marubayashi, S., Zibinsky, M., Hu, D.X., Robles, O., Jackson, J.J., and Baloche, V. (2022). EBV+ tumors exploit tumor cell-intrinsic and-extrinsic mechanisms to produce regulatory T cell-recruiting chemokines CCL17 and CCL22. PLoS Pathog., 18.","DOI":"10.1371\/journal.ppat.1010200"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Matsuo, K., Yoshie, O., and Nakayama, T. (2021). Multifaceted roles of chemokines and chemokine receptors in tumor immunity. Cancers, 13.","DOI":"10.3390\/cancers13236132"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"216293","DOI":"10.1016\/j.canlet.2023.216293","article-title":"Tertiary lymphoid structures and cytokines interconnections: The implication in cancer immunotherapy","volume":"568","author":"Li","year":"2023","journal-title":"Cancer Lett."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1186\/s12943-024-02183-9","article-title":"Crosstalk of pyroptosis and cytokine in the tumor microenvironment: From mechanisms to clinical implication","volume":"23","author":"Wang","year":"2024","journal-title":"Mol. Cancer"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Qin, M., Wang, D., Fang, Y., Zheng, Z., Liu, X., Wu, F., Wang, L., Li, X., Hui, B., and Ma, S. (2021). Current perspectives on B lymphocytes in the immunobiology of hepatocellular carcinoma. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.647854"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"929","DOI":"10.4049\/jimmunol.2100656","article-title":"Microfluidic squeezing enables MHC class I antigen presentation by diverse immune cells to elicit CD8+ T cell responses with antitumor activity","volume":"208","author":"Booty","year":"2022","journal-title":"J. Immunol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"7657","DOI":"10.1039\/D4CS00421C","article-title":"Lymphoid organ-targeted nanomaterials for immunomodulation of cancer, inflammation, and beyond","volume":"53","author":"Hsu","year":"2024","journal-title":"Chem. Soc. Rev."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jconrel.2023.05.032","article-title":"Bispecific antibodies for targeted delivery of anti-cancer therapeutic agents: A review","volume":"359","author":"Beishenaliev","year":"2023","journal-title":"J. Control. Release"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/imr.13427","article-title":"Fc effector function of immune checkpoint blocking antibodies in oncology","volume":"328","author":"Martineau","year":"2024","journal-title":"Immunol. Rev."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Mata-Molanes, J.J., Rebollo-Liceaga, J., Mart\u00ednez-Navarro, E.M., Manzano, R.G., Brugarolas, A., Juan, M., and Sureda, M. (2022). Relevance of Fc gamma receptor polymorphisms in cancer therapy with monoclonal antibodies. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.926289"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"4290","DOI":"10.1158\/0008-5472.CAN-20-3773","article-title":"Tumor-infiltrating B lymphocyte profiling identifies IgG-biased, clonally expanded prognostic phenotypes in triple-negative breast cancer","volume":"81","author":"Harris","year":"2021","journal-title":"Cancer Res."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Chen, W., Zhang, L., Gao, M., Zhang, N., Wang, R., Liu, Y., Niu, Y., and Jia, L. (2025). Role of tertiary lymphoid structures and B cells in clinical immunotherapy of gastric cancer. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1519034"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Farhangnia, P., Ghomi, S.M., Akbarpour, M., and Delbandi, A.A. (2023). Bispecific antibodies targeting CTLA-4: Game-changer troopers in cancer immunotherapy. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1155778"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/s41586-020-2931-3","article-title":"Defining HPV-specific B cell responses in patients with head and neck cancer","volume":"597","author":"Wieland","year":"2021","journal-title":"Nature"},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Lam, B.M., and Verrill, C. (2023). Clinical significance of tumour-infiltrating B lymphocytes (TIL-Bs) in breast cancer: A systematic literature review. Cancers, 15.","DOI":"10.3390\/cancers15041164"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/s41568-022-00466-1","article-title":"Tumour-infiltrating B cells: Immunological mechanisms, clinical impact and therapeutic opportunities","volume":"22","author":"Laumont","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Angelico, G., Broggi, G., Tinnirello, G., Puzzo, L., Vecchio, G.M., Salvatorelli, L., Memeo, L., Santoro, A., Farina, J., and Mul\u00e9, A. (2023). Tumor infiltrating lymphocytes (TILS) and PD-L1 expression in breast cancer: A review of current evidence and prognostic implications from pathologist\u2019s perspective. Cancers, 15.","DOI":"10.20944\/preprints202306.0507.v1"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1186\/s12935-021-02004-9","article-title":"Tumor-infiltrating B cells as a favorable prognostic biomarker in breast cancer: A systematic review and meta-analysis","volume":"21","author":"Qin","year":"2021","journal-title":"Cancer Cell Int."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Kang, W., Feng, Z., Luo, J., He, Z., Liu, J., Wu, J., and Rong, P. (2021). Tertiary lymphoid structures in cancer: The double-edged sword role in antitumor immunity and potential therapeutic induction strategies. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.689270"},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Zhai, K., Ma, Y., Gao, X., Ru, K., and Zhao, M. (2025). Tertiary lymphoid structures in esophageal cancer: A novel target for immunotherapy. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1543322"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Cai, D., Yu, H., Wang, X., Mao, Y., Liang, M., Lu, X., Shen, X., and Guan, W. (2023). Turning tertiary lymphoid structures (TLS) into hot spots: Values of TLS in gastrointestinal tumors. Cancers, 15.","DOI":"10.3390\/cancers15020367"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"e70063","DOI":"10.1111\/imr.70063","article-title":"Tertiary lymphoid structures across organs: Context, composition, and clinical levers","volume":"335","author":"Guillaume","year":"2025","journal-title":"Immunol. Rev."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/cac2.12525","article-title":"Targeting autophagy overcomes cancer-intrinsic resistance to CAR-T immunotherapy in B-cell malignancies","volume":"44","author":"Tang","year":"2024","journal-title":"Cancer Commun."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Rupp, L., Dietsche, I., Kiessler, M., Sommer, U., Muckenhuber, A., Steiger, K., van Eijck, C.W., Richter, L., Istvanffy, R., and J\u00e4ger, C. (2024). Neoadjuvant chemotherapy is associated with suppression of the B cell-centered immune landscape in pancreatic ductal adenocarcinoma. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1378190"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ccell.2022.02.002","article-title":"Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer","volume":"40","author":"Patil","year":"2022","journal-title":"Cancer Cell"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41419-025-08254-z","article-title":"Targeting tumour-infiltrating B cells: Mechanisms and advances in cancer therapy","volume":"17","author":"Yang","year":"2025","journal-title":"Cell Death Dis."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.ccell.2023.01.009","article-title":"Metabolic programming and immune suppression in the tumor microenvironment","volume":"41","author":"Arner","year":"2023","journal-title":"Cancer Cell"},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Liu, K., Huang, A., Nie, J., Tan, J., Xing, S., Qu, Y., and Jiang, K. (2021). IL-35 regulates the function of immune cells in tumor microenvironment. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.683332"},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Chen, L., Huang, Q., and Zhou, P. (2025). Multimodal cell-cell communication driving CD8+ T cell dysfunction and immune evasion. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1691746"},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Lu, S., Wang, C., Ma, J., and Wang, Y. (2024). Metabolic mediators: Microbial-derived metabolites as key regulators of anti-tumor immunity, immunotherapy, and chemotherapy. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1456030"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/s41392-026-02902-2","article-title":"Humoral immunity in cancer","volume":"11","author":"Leonard","year":"2026","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Pe\u00f1a-Romero, A.C., and Orenes-Pi\u00f1ero, E. (2022). Dual effect of immune cells within tumour microenvironment: Pro-and anti-tumour effects and their triggers. Cancers, 14.","DOI":"10.3390\/cancers14071681"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.cell.2024.11.007","article-title":"YTHDF2 promotes ATP synthesis and immune evasion in B cell malignancies","volume":"188","author":"Chen","year":"2025","journal-title":"Cell"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"e012121","DOI":"10.1136\/jitc-2025-012121","article-title":"Memory B cell subset shapes antitumor immunity and response to PD-1 blockade in mismatch repair-deficient colorectal cancers","volume":"14","author":"Huang","year":"2026","journal-title":"J. Immunother. Cancer"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41577-023-00973-8","article-title":"Immunotherapy combination approaches: Mechanisms, biomarkers and clinical observations","volume":"24","author":"Butterfield","year":"2024","journal-title":"Nat. Rev. Immunol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"e20231263","DOI":"10.1084\/jem.20231263","article-title":"ICOS costimulation in combination with CTLA-4 blockade remodels tumor-associated macrophages toward an antitumor phenotype","volume":"221","author":"Sharma","year":"2024","journal-title":"J. Exp. Med."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Pinard, C.J., Lagree, A., Lu, F.I., Klein, J., Oblak, M.L., Salgado, R., Cardenas, J.C., Brunetti, B., Muscatello, L.V., and Sarli, G. (2022). Comparative evaluation of tumor-infiltrating lymphocytes in companion animals: Immuno-oncology as a relevant translational model for cancer therapy. Cancers, 14.","DOI":"10.3390\/cancers14205008"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"e70478","DOI":"10.1002\/mco2.70478","article-title":"Radiation-Induced biological effects: Molecular and cellular mechanism, and applications to radiation\/nuclear emergency and cancer therapy","volume":"6","author":"Hu","year":"2025","journal-title":"MedComm"},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Rafei, H., Upadhyay, R., and Sharma, P. (2026). A guide to CAR T cell therapies: Development, current status and future prospects. Nat. Rev. Immunol., 1\u201324.","DOI":"10.1038\/s41577-026-01322-1"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13046-022-02327-z","article-title":"CAR race to cancer immunotherapy: From CAR T, CAR NK to CAR macrophage therapy","volume":"41","author":"Pan","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s41591-023-02754-1","article-title":"Impact of tumor microenvironment on efficacy of anti-CD19 CAR T cell therapy or chemotherapy and transplant in large B cell lymphoma","volume":"30","author":"Locke","year":"2024","journal-title":"Nat. Med."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"e005644","DOI":"10.1136\/jitc-2022-005644","article-title":"Activated B cells suppress T-cell function through metabolic competition","volume":"10","author":"Imahashi","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.immuni.2022.02.001","article-title":"Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer","volume":"55","author":"Meylan","year":"2022","journal-title":"Immunity"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/cei\/uxac029","article-title":"Mechanisms of induction of regulatory B cells in the tumour microenvironment and their contribution to immunosuppression and pro-tumour responses","volume":"209","author":"Blair","year":"2022","journal-title":"Clin. Exp. Immunol."},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Stout, A., Facey, N., Bhatnagar, A., Rice, K., Berditchevski, F., Kearns, D., Metcalf, A., Elghobashy, A., and Shaaban, A.M. (2024). Profiling of Tumour-Infiltrating Lymphocytes and Tumour-Associated Macrophages in Ovarian Epithelial Cancer\u2014Relation to Tumour Characteristics and Impact on Prognosis. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25084524"},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Rastogi, I., Jeon, D., Moseman, J.E., Muralidhar, A., Potluri, H.K., and McNeel, D.G. (2022). Role of B cells as antigen presenting cells. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.954936"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41568-024-00690-x","article-title":"Cancer therapy with antibodies","volume":"24","author":"Paul","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"201146","DOI":"10.1016\/j.omton.2026.201146","article-title":"Targeted therapies in pediatric oncology: A start","volume":"34","author":"Shah","year":"2026","journal-title":"Mol. Ther. Oncol."},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Djureinovic, D., Wang, M., and Kluger, H.M. (2021). Agonistic CD40 antibodies in cancer treatment. Cancers, 13.","DOI":"10.3390\/cancers13061302"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.4110\/in.2024.24.e34","article-title":"Current developments in NK cell engagers for cancer immunotherapy: Focus on CD16A and NKp46","volume":"24","author":"Shin","year":"2024","journal-title":"Immune Netw."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"D\u00e9sage, A.L., Karpathiou, G., Peoc\u2019h, M., and Froudarakis, M.E. (2021). The immune microenvironment of malignant pleural mesothelioma: A literature review. Cancers, 13.","DOI":"10.3390\/cancers13133205"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1080\/14712598.2021.1828338","article-title":"Clinically feasible and prospective immunotherapeutic interventions in multidirectional comprehensive treatment of cancer","volume":"21","author":"Seledtsov","year":"2021","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Palma, M. (2025). Advancing breast cancer treatment: The role of immunotherapy and cancer vaccines in overcoming therapeutic challenges. Vaccines, 13.","DOI":"10.3390\/vaccines13040344"},{"key":"ref_129","first-page":"106","article-title":"CRISPR enabled precision oncology: From gene editing to tumor microenvironment remodeling","volume":"2","author":"Li","year":"2026","journal-title":"Med. Res."},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Amiri, M., Moaveni, A.K., Majidi Zolbin, M., Shademan, B., and Nourazarian, A. (2024). Optimizing cancer treatment: The synergistic potential of CAR-T cell therapy and CRISPR\/Cas9. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1462697"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"9040","DOI":"10.1039\/D4NR05160B","article-title":"Smart MXene-based microrobots for targeted drug delivery and synergistic therapies","volume":"17","author":"Iravani","year":"2025","journal-title":"Nanoscale"},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Chen, Y., Dahal, P.K., Mosharaf, P., Shahjalal, M., and Mahumud, R.A. (2025). Assessing the clinical effectiveness of radioimmunotherapy with combined radionuclide\/monoclonal antibody conjugates in cancer treatment: Insights from randomised clinical trials. Cancers, 17.","DOI":"10.3390\/cancers17091413"},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Deng, M., Xiong, J., Hu, D., Kong, Z., and Li, T. (2025). Case Report: Efficacy of ofatumumab in refractory anti-NMDAR encephalitis: Case series and literature review. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1557210"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1","DOI":"10.59049\/2790-0231.10.1.2262","article-title":"Revolutionizing the treatment of cancer using CAR T Cells and Bispecific Antibodies","volume":"10","author":"Medapati","year":"2024","journal-title":"Palest. Med. Pharm. J."},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Cao, W., Ma, S., Han, L., Xing, H., Li, Y., Jiang, Z., Guo, X., and Yu, J. (2025). Bispecific antibodies in immunotherapy for acute leukemia: Latest updates from the 66th annual meeting of the American society of hematology, 2024. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1566202"},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Jiang, Y., Dong, S., and Wang, Y. (2025). Antibody\u2013Drug conjugates targeting CD30 in T-cell lymphomas: Clinical progression and mechanism. Cancers, 17.","DOI":"10.3390\/cancers17030496"},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Xiong, J., Chi, H., Yang, G., Zhao, S., Zhang, J., Tran, L.J., Xia, Z., Yang, F., and Tian, G. (2023). Revolutionizing anti-tumor therapy: Unleashing the potential of B cell-derived exosomes. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1188760"},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Qin, V.M., D\u2019Souza, C., Neeson, P.J., and Zhu, J.J. (2021). Chimeric antigen receptor beyond CAR-T cells. Cancers, 13.","DOI":"10.3390\/cancers13030404"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"e008636","DOI":"10.1136\/jitc-2023-008636","article-title":"B cells and the coordination of immune checkpoint inhibitor response in patients with solid tumors","volume":"12","author":"Flippot","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/s43018-021-00241-5","article-title":"Engineering-enhanced CAR T cells for improved cancer therapy","volume":"2","author":"Milone","year":"2021","journal-title":"Nat. Cancer"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"413","DOI":"10.2147\/ITT.S474659","article-title":"Revolutionizing immunotherapy: Unveiling new horizons, confronting challenges, and navigating therapeutic frontiers in CAR-T Cell-Based gene therapies","volume":"13","author":"Srivastava","year":"2024","journal-title":"ImmunoTargets Ther."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41573-024-00896-6","article-title":"The present and future of bispecific antibodies for cancer therapy","volume":"23","author":"Klein","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3389\/fimmu.2023.1197364","article-title":"Immune-related adverse effects of checkpoint immunotherapy and implications for the treatment of patients with cancer and autoimmune diseases","volume":"14","author":"Ibis","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1021\/acs.accounts.2c00360","article-title":"Rational design of T-cell-and B-cell-based therapeutic cancer vaccines","volume":"55","author":"Li","year":"2022","journal-title":"Acc. Chem. Res."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41392-023-01674-3","article-title":"Therapeutic cancer vaccines: Advancements, challenges and prospects","volume":"8","author":"Fan","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40364-023-00460-1","article-title":"Roles and mechanisms of tumour-infiltrating B cells in human cancer: A new force in immunotherapy","volume":"11","author":"Zhang","year":"2023","journal-title":"Biomark. Res."},{"key":"ref_147","doi-asserted-by":"crossref","unstructured":"Kang, E.Y., Wang, D., Kaniowski, D., Tang, W., Davis, A., Swiderski, P., and Kortylewski, M. (2025). Myeloid cell-targeted lipid nanoparticles for B cell lymphoma immunotherapy. Mol. Ther. Nucleic Acids, 36.","DOI":"10.1016\/j.omtn.2025.102773"},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Jiang, Y., Jiang, B., Wang, Z., Li, Y., Cheung, J.C., Yin, B., and Wong, S.H. (2024). Nucleic acid armor: Fortifying RNA therapeutics through delivery and targeting innovations for immunotherapy. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25168888"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.ymthe.2025.02.047","article-title":"Using aptamers for targeted delivery of RNA therapies","volume":"33","author":"Driscoll","year":"2025","journal-title":"Mol. Ther."},{"key":"ref_150","doi-asserted-by":"crossref","unstructured":"Hazan-Halevy, I., Landesman-Milo, D., Kon, E., Dammes, N., and Peer, D. (2022). Extrahepatic delivery of RNA to immune cells. RNA Therapeutics, Academic Press.","DOI":"10.1016\/B978-0-12-821595-1.00001-4"},{"key":"ref_151","doi-asserted-by":"crossref","unstructured":"Guo, H., Yang, J., Wang, H., Liu, X., Liu, Y., and Zhou, K. (2022). Reshaping the tumor microenvironment: The versatility of immunomodulatory drugs in B-cell neoplasms. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1017990"},{"key":"ref_152","doi-asserted-by":"crossref","unstructured":"Ioannou, N., Jain, K., and Ramsay, A.G. (2021). Immunomodulatory drugs for the treatment of B cell malignancies. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22168572"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"2300445","DOI":"10.1002\/adtp.202300445","article-title":"Oncolytic viruses in cancer immunotherapy","volume":"7","author":"Li","year":"2024","journal-title":"Adv. Ther."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1038\/s41375-020-0828-7","article-title":"Oncolytic measles virus therapy enhances tumor antigen-specific T-cell responses in patients with multiple myeloma","volume":"34","author":"Packiriswamy","year":"2020","journal-title":"Leukemia"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1080\/13543784.2020.1814253","article-title":"CD38: Targeted therapy in multiple myeloma and therapeutic potential for solid cancers","volume":"29","author":"Jiao","year":"2020","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_156","doi-asserted-by":"crossref","unstructured":"Lin, C.H., Tariq, M.J., Ullah, F., Sannareddy, A., Khalid, F., Abbas, H., Bader, A., Samaras, C., Valent, J., and Khouri, J. (2024). Current novel targeted therapeutic strategies in multiple myeloma. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25116192"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1016\/j.ymthe.2021.09.019","article-title":"Genome edited B cells: A new frontier in immune cell therapies","volume":"29","author":"Rogers","year":"2021","journal-title":"Mol. Ther."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/s41419-020-03187-1","article-title":"Engineering of \u03b1-PD-1 antibody-expressing long-lived plasma cells by CRISPR\/Cas9-mediated targeted gene integration","volume":"11","author":"Luo","year":"2020","journal-title":"Cell Death Dis."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"e2423853122","DOI":"10.1073\/pnas.2423853122","article-title":"Cell-based glycoengineering for production of homogeneous and specific glycoform-enriched antibodies with improved effector functions","volume":"122","author":"Huang","year":"2025","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1146\/annurev-bioeng-082721-024500","article-title":"Improving antibody therapeutics by manipulating the Fc domain: Immunological and structural considerations","volume":"24","author":"Delidakis","year":"2022","journal-title":"Annu. Rev. Biomed. Eng."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"eadu3624","DOI":"10.1126\/sciadv.adu3624","article-title":"Antigen-specific B cell response regulation by IL-10\u2013producing tolerogenic dendritic cells","volume":"11","author":"Morali","year":"2025","journal-title":"Sci. Adv."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.immuni.2026.01.015","article-title":"B cell-intrinsic IL-2 signaling regulates inflammation by promoting IL-10 expression in CD25+ age-associated B cells","volume":"59","author":"Gauthier","year":"2026","journal-title":"Immunity"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrclinonc.2016.168","article-title":"PD-1\u2013PD-L1 immune-checkpoint blockade in B-cell lymphomas","volume":"14","author":"Goodman","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s40257-024-00907-7","article-title":"Overcoming Resistance Mechanisms to Melanoma Immunotherapy","volume":"26","author":"Zheng","year":"2025","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_165","doi-asserted-by":"crossref","unstructured":"Dai, M., Chen, S., Wang, Y., Fan, J., Pan, X., Sang, C., Liu, Y., Hu, M., Ma, L., and Wang, S. (2025). F-box proteins at the crossroads of ubiquitination and tumor immunity: Regulatory networks and immunotherapy strategies. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1596344"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/s41590-025-02102-0","article-title":"B cell immunometabolism in health and disease","volume":"26","author":"Martinis","year":"2025","journal-title":"Nat. Immunol."}],"container-title":["Antibodies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4468\/15\/5\/87\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T11:59:18Z","timestamp":1789646358000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4468\/15\/5\/87"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":166,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["antib15050087"],"URL":"https:\/\/doi.org\/10.3390\/antib15050087","relation":{},"ISSN":["2073-4468"],"issn-type":[{"value":"2073-4468","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]}}}